Carcinoma, Invasive Ductal, Breast Clinical Trial
Official title:
A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.
| Verified date | May 2010 |
| Source | Chinese Academy of Medical Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | China: Food and Drug Administration |
| Study type | Interventional |
It is a phase III trial to explore the efficacy and safety of vinorelbine plus capecitabine (NX) and docetaxel plus capecitabine (TX) as first line treatment followed by capecitabine alone till Progressive Disease(PD). We plan to enroll 200 pts for limited budget and the non-inferior trend of the two curves is anticipated.
| Status | Recruiting |
| Enrollment | 200 |
| Est. completion date | August 2015 |
| Est. primary completion date | May 2015 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Written and signed informed consent prior to beginning specific protocol procedures. - Pathologically confirmed breast cancer and documented metastatic or locally advanced disease. Measurable disease (RECIST criteria) - with at least 1 lesion measurable by radiological method - KPS>=70 - Adjuvant and/or Neoadjuvant chemotherapy, including an anthracycline was permitted - Hormone therapy for early-stage or metastatic breast cancer was permitted if hormonal receptor positive. - Treatment with Herceptin for early-stage or metastatic breast cancer is permitted if HER2 positive - Patients had to have concluded prior radiation therapy at least 14 days before enrollment. - Laboratory requirements: - Hematology Absolute neutrophil count>=1,500 /µl; Platelets>=100,000 /µl; Hemoglobin>=10 g/dl - Liver function Total bilirubin<=2 times ULN ASAT (SGOT) and ALAT (SGPT)<=2.5 times UNL without liver metastasis or <=5.0 times if liver metastasis Glucose<=200 mg/dL - Renal function Serum creatinine<=140 mol/l - Life expectancy of at least 12 weeks - Patients must be accessible for treatment and follow-up. - Patients should have recovered from the acute reversible effects of prior treatment. This generally means at least 3 weeks should have elapsed since prior chemotherapy, adjuvant or Neoadjuvant treatment. and at least 4 weeks since prior (radical) radiotherapy or major surgery Exclusion Criteria: - Women who are pregnant or breast feeding - History of brain and/or leptomeningeal metastases - Previous chemotherapy for metastatic breast cancer - Past or current history of malignant neoplasm other than breast carcinoma, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years - Pre-existing neuropathy grade 1 according to the NCIC-CTC 3.0 - Psychiatric disorders or other conditions which would prevent pt. compliance - Other serious illness or medical condition: - Congestive heart failure, or unstable angina pectoris, previous history of myocardial infarction within 6 month prior to study entry, uncontrolled hypertension as determined by the Investigator or high risk uncontrolled, arrhythmia. - History of significant neurological or psychiatric disorders including psychotic disorders, dementia of seizures that would prohibit the understanding and giving of informed consent. - Active uncontrolled infection. - Unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of Corticosteroids. - Inability to take and/or absorb oral medicine - Prior treatment with an docetaxel and/or capecitabine and/or vinorbine - Concurrent treatment with other experimental drugs, or participation in another clinical trial with any investigational drug within 30 days prior to study entry |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| China | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Chinese Academy of Medical Sciences | Hoffmann-La Roche |
China,
Chan A, Verrill M. Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer. 2009 Sep;45(13):2253-65. doi: 10.1016/j.ejca.2009.04.031. Epub 2009 May 20. Review. — View Citation
Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res. 2006 May-Jun;26(3B):2451-6. — View Citation
O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreate — View Citation
Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 1999 Aug;35(8):1194-201. — View Citation
Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol. 2005 Jan;16(1):64-9. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Progression free survival(PFS) | Progress free survival is defined as the time from first dose of test drug to the first recording of disease progression or the date of death in patients with no evidence of disease progression. In addition to hazard ratios and associated 95% confidence intervals, the results from these analyses will, for each treatment arm, also be summarized by Kaplan-Meier plots, medians and 95% confidence intervals. |
Up to 2 years until disease progression or death | No |
| Secondary | Safety Profiles | All adverse events occurring up to 28 days after last intake of study medication are to be recorded in the case report form. Safety profile will be analyzed by tabulating its occurring frequency and percentage per patient using NCI-CTC version 3.0. ?2 statistics will be used to test the differences in toxicities between the two treatment arms. SAEs will be reported according to ICH-GCP. |
Up to 2 years until 28 days after last intake of study medication | Yes |
| Secondary | Overall Survival | Survival will be measured from the date of first dose of test drug to the date of death (any cause) or to the date of last contact. | Up to 3 years after last intake of study medication | No |
| Secondary | Response Rate | Tumor responses were assessed on the basis of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 at 6-week intervals then at 12-week intervals after disease progression. | Up to 2 years until disease progression, unacceptable toxicity or death | No |